BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its price target upped by JPMorgan Chase & Co. from $111.00 to $120.00 in a research note issued to investors on Thursday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biotechnology company’s stock.
BMRN has been the topic of a number of other reports. StockNews.com raised shares of BioMarin Pharmaceutical from a hold rating to a buy rating in a research note on Thursday, August 8th. Stifel Nicolaus increased their price target on shares of BioMarin Pharmaceutical from $112.00 to $115.00 and gave the company a buy rating in a research report on Wednesday, August 21st. Canaccord Genuity Group restated a hold rating and set a $89.00 price objective on shares of BioMarin Pharmaceutical in a research report on Thursday, July 25th. Cantor Fitzgerald reiterated an overweight rating and set a $110.00 target price on shares of BioMarin Pharmaceutical in a report on Monday, August 5th. Finally, Scotiabank boosted their price target on BioMarin Pharmaceutical from $86.00 to $95.00 and gave the stock a sector perform rating in a report on Thursday. Eight investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and an average target price of $106.10.
Read Our Latest Report on BMRN
BioMarin Pharmaceutical Trading Down 1.2 %
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) last issued its earnings results on Monday, August 5th. The biotechnology company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.38 by $0.39. BioMarin Pharmaceutical had a net margin of 9.91% and a return on equity of 6.91%. The company had revenue of $712.03 million for the quarter, compared to analyst estimates of $660.51 million. Equities research analysts expect that BioMarin Pharmaceutical will post 2.35 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BMRN. Sanctuary Advisors LLC acquired a new stake in BioMarin Pharmaceutical during the second quarter worth about $1,783,000. Teachers Retirement System of The State of Kentucky grew its holdings in shares of BioMarin Pharmaceutical by 17.4% during the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 194,207 shares of the biotechnology company’s stock worth $15,990,000 after purchasing an additional 28,837 shares during the period. Novo Holdings A S grew its holdings in shares of BioMarin Pharmaceutical by 8.9% during the 2nd quarter. Novo Holdings A S now owns 490,000 shares of the biotechnology company’s stock worth $40,342,000 after purchasing an additional 40,000 shares during the period. NewEdge Advisors LLC increased its position in BioMarin Pharmaceutical by 3,931.5% during the 2nd quarter. NewEdge Advisors LLC now owns 10,885 shares of the biotechnology company’s stock worth $896,000 after purchasing an additional 10,615 shares in the last quarter. Finally, Creative Planning raised its holdings in BioMarin Pharmaceutical by 4.6% in the second quarter. Creative Planning now owns 11,825 shares of the biotechnology company’s stock valued at $974,000 after buying an additional 524 shares during the period. Institutional investors and hedge funds own 98.71% of the company’s stock.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Further Reading
- Five stocks we like better than BioMarin Pharmaceutical
- How to Use the MarketBeat Dividend Calculator
- Is Merck Stock Undervalued After Its Colossal Earnings Growth?
- What is the NASDAQ Stock Exchange?
- Top 5 ETFs for Every Investor: From Semiconductors to Defense
- The 3 Best Fintech Stocks to Buy Now
- Blade Air Mobility: This Under-the-Radar Stock Could Double Soon
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.